Passage BIO, Inc. (PASG) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Passage BIO, Inc. is a clinical-stage genetic medicines company focused on neurodegenerative diseases. Its lead product candidate, PBFT02, targets frontotemporal dementia (FTD-GRN) and is being evaluated for FTD-C9orf72 and ALS. The company operates as a single segment and is currently in a pre-revenue stage, relying on cash reserves and potential strategic transactions to fund operations.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,559) | $(15,405) |
| Loss Per Share (Basic & Diluted) | $(2.36) | $(4.87) |
| Operating Cash Flow | $(12,987) | $(13,847) |
| Cash and Cash Equivalents (End of Period) | $33,336 | $63,357 |
| Total Assets | $36,462 | $62,281 |
| Total Liabilities | $24,710 | $43,526 |
| Stockholders' Equity | $11,752 | $46,706 |
Note: The company has no revenue. Expenses are primarily Research & Development (R&D) and General & Administrative (G&A). The company holds $13.8 million in non-refundable sublicense and transition service payments from Gemma Biotherapeutics, recorded as a liability until revenue recognition criteria are met.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $7.8 million (51%) compared to Q1 2025, driven by significant cost-cutting measures and a one-time net gain on lease termination.
- Expense Reductions:
- R&D expenses decreased by $3.6 million to $4.1 million, primarily due to lower headcount (following a 55% reduction in Jan 2025) and reduced facility costs.
- G&A expenses decreased by $1.3 million to $4.8 million due to lower wages and share-based compensation.
- Lease Termination: The company terminated its Hopewell, NJ laboratory lease in March 2026, recognizing a net gain of $0.6 million (offsetting a $3.2 million loss on asset disposal with a $3.8 million gain on lease liability write-off).
- Asset Base Contraction: Total assets decreased by $25.8 million, largely due to the write-off of Right-of-Use (ROU) assets and property/equipment associated with the Hopewell lease termination.
- Cash Burn: Cash and cash equivalents declined by $13.0 million during the quarter, leaving $33.3 million on hand.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern within one year. Current cash ($33.3 million) is deemed insufficient to meet capital requirements for the next 12 months.
- Strategic Review: On April 20, 2026, the company announced a review of strategic alternatives, including mergers, acquisitions, asset sales, or partnerships.
- Restructuring Plan: On April 28, 2026, the company announced a workforce reduction of approximately 75% to decrease operating expenses. Estimated severance costs are $3.3 million, expected to be recorded in Q2 2026.
- Clinical Development: The FDA indicated that a randomized controlled registrational study is required for PBFT02 in FTD-GRN. Due to ethical, logistical, and financial challenges, the company is evaluating next steps for this program and others (FTD-C9orf72, ALS).
- Financing Capacity: The company has an At-The-Market (ATM) facility with $15.8 million of remaining capacity as of March 31, 2026, though it is currently limited by public float restrictions.
- Legal Proceedings: A pending appeal regarding a former employee's stock settlement claim is before the Pennsylvania Supreme Court; the company won at the trial and appellate levels previously.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $33.3 million cash balance against the projected burn rate post-restructuring and the timeline for the strategic review.
- Strategic Alternatives: Monitor for updates on the strategic review initiated in April 2026, as a transaction may be necessary to avoid insolvency.
- Restructuring Costs: Confirm the actual impact of the 75% workforce reduction and the $3.3 million severance charge on Q2 2026 financials.
- Regulatory Pathway: Assess the feasibility and cost of the FDA-required randomized controlled trial for PBFT02 and the company's decision on proceeding.
- Revenue Recognition: Track the status of the $13.8 million in payments received from Gemma Biotherapeutics to determine when, if ever, they will be recognized as revenue.
- ATM Facility: Monitor the company's ability to utilize the remaining $15.8 million ATM capacity given current market conditions and float limitations.